NCT05592665View on ClinicalTrials.gov

PRO-VISION: Patient Reported Outcomes-Based Monitoring of VEGF-Inhibitor Side Effects in ONcology

NAActive, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

March 18, 2022

Primary Completion Date

January 16, 2027

Study Completion Date

January 16, 2031

Conditions
Renal Cell Carcinoma
Interventions
OTHER

Survey Questionnaire

Study participants will complete several questionnaires/assessments via PRO-Core standardized email communication or via telephone with a study team member.

Trial Locations (1)

27514

Lineberger Comprehensive Cancer Center, Chapel Hill

All Listed Sponsors
collaborator

Doris Duke Charitable Foundation

OTHER

lead

UNC Lineberger Comprehensive Cancer Center

OTHER